key: cord-0874916-v399ucup
authors: Telo, Silvi; Farolfi, Andrea; Castellucci, Paolo; Antonacci, Filippo; Solli, Piergiorgio; Mosconi, Cristina; Fanti, Stefano; Agosti, Roberto; Morigi, Joshua James; Nanni, Cristina
title: A case of [(68)Ga]Ga-FAPI-46-avid and [(18)F]F-FDG-negative COVID-19 pneumonia sequelae
date: 2022-02-18
journal: Eur J Nucl Med Mol Imaging
DOI: 10.1007/s00259-022-05720-0
sha: 6ba94b6db39c7d1868adf659633c11566cdda8d8
doc_id: 874916
cord_uid: v399ucup

nan

A 72-year-old woman with COVID-19 respiratory syndrome symptoms underwent a chest CT scan (CT) for investigation. The CT detected a lung mass with no evidence of pneumonia (Fig. a) ; however, an RT-PCR nasopharyngeal swab (PCR) resulted positive for COVID-19 infection. Subsequent high-resolution CT (HRCT) performed 5 days later identified diffuse, bilateral peripheral ground-glass-opacities (GGO) (Fig. b , red arrow). After returning a negative PCR, FAPI PET/CT targets the fibroblast activation protein (FAP) which is overexpressed in activated fibroblasts highly present in tumor stroma, but also in benign processes such as fibrosis [1] .

Interestingly, GGO in this patient demonstrated no significant [ 18 F]F-FDG-uptake (SUVmax = 3.3; liver SUVmax = 4.5; blood-pool SUVmax = 3.7) paired with increased [ 68 Ga]Ga-FAPI-46 uptake (SUVmax = 8.2), suggesting no active inflammation with persisting activated fibroblasts.

Pulmonary fibrosis was reported both in COVID-19 patients and pathological specimens [2, 3] .

In this case, fibrosis was not identified at HRCT nor reviewing surgical slides of previously resected healthy lung parenchyma margins surrounding lung cancer. HRCT demonstrated instead crazy-paving with superimposed interlobular-septal thickening which can be a feature of lung fibrosis [4] , with persistence 3 months after.

To the best of our knowledge, this is the first reported case of FAPI-avid COVID-19 lung infection sequelae. Although lung fibrosis/COVID-19 correlation needs to be investigated in further studies, developing tools to estimate the burden of pulmonary fibrosis or to discriminate between inflammation and fibrosis in patients with lung infections such as COVID-19 could be helpful to predict disease long term effects [5] .

Author contribution Silvi Telo, Cristina Nanni, and Andrea Farolfi contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Silvi Telo, Cristina Nanni, and Andrea Farolfi. The first draft of the manuscript was written by Silvi Telo and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Ethics approval This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee (EudraCT 2020-005549-17).

The patient gave written consent for the use of anonymous data for research purpose (CE approval: EudraCT 2020-005549-17).

The authors declare no competing interests.

Haberkorn U. Targeting of activated fibroblasts for imaging and therapy

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

Correlation of autopsy pathological findings and imaging features from 9 fatal cases of COVID-19 pneumonia

The crazy-paving pattern: a radiological-pathological correlation

Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging